通过CARM1-介导的MAP2K4甲基化增强了MAP2K4的致癌功能,并且在三阴性乳腺癌中构成了可向的依赖性
Eui-Jun Kim1,2, Yidan Wang1,2, Yu-Lin Chen1,2
1McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, Wisconsin.
Cancer research
|May 29, 2025
概括
在三阴性乳腺癌 (TNBC) 中,协活性剂相关的阿尔金因甲基转移酶1 (CARM1) 抑制激活了AKT,导致了耐药性. 将CARM1抑制剂与PI3K抑制剂结合在一起,在TNBC中显示出协同作用的抗癌效应.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 同活性剂相关的阿尔金因甲基转移酶1 (CARM1) 在三阴性乳腺癌 (TNBC) 中过度表达.
- 目前正在开发CARM1抑制剂 (CARM1i),但CARM1i治疗可以矛盾地增加CARM1水平并激活AKT,可能导致耐药性.
研究的目的:
- 研究CARM1抑制影响TNBC中信号通路的机制.
- 确定潜在的组合疗法,以克服CARM1i耐药性.
主要方法:
- 在TNBC细胞中研究了MAP2K4的CARM1甲基化.
- 评估了CARM1i对AKT和JNK信号通路的影响.
- 在TNBC模型中评估了将CARM1i与PI3K抑制剂结合的疗效.
主要成果:
- CARM1在氨酸58处甲基化MAP2K4,促进其核定位和JNK信号的激活,从而驱动扩散和转移.
- CARM1i治疗抑制了MAP2K4甲基化,通过废除MAP2K4-PI3K信号反循环,导致AKT激活.
- 与CARM1i和PI3K抑制剂的联合疗法在TNBC细胞系,有机体和患者衍生的异种移植中显示出协同作用的抗癌作用.
结论:
- 抑制CARM1会破坏MAP2K4-PI3K信号轴,这为组合疗法提供了理由.
- 将CARM1i与PI3K抑制剂结合起来可以提高TNBC的治疗敏感性.
- 这项研究提供了一种新的治疗策略,以克服TNBC中对CARM1抑制剂的耐药性.
相关概念视频
MAPK Signaling Cascades
6.2K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.2K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Microtubule Associated Proteins (MAPs)
4.6K
Microtubule function and architecture are regulated by an array of specialized proteins called microtubule-associated proteins or MAPs. These proteins are widespread across different organisms and have conserved protein motifs, like the multi-TOG domain for tubulin binding found in the CLASP family of MAPs. Some MAPs are lineage-specific based on their conserved domains. Their functions depend upon the cytoskeletal architecture and cell type they are located within. In-plant cells, a specific...
4.6K
Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Interactions Between Signaling Pathways
6.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K


